Compare · CLPT vs WST
CLPT vs WST
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $21.02B, about 62.7x CLPT ($335.2M).
- Over the past year, CLPT is down 19.5% and WST is up 42.6% - WST leads by 62.1 points.
- WST has been more active in the news (7 items in the past 4 weeks vs 5 for CLPT).
- WST has more recent analyst coverage (15 ratings vs 4 for CLPT).
- Company
- ClearPoint Neuro Inc.
- West Pharmaceutical Services Inc.
- Price
- $11.20+0.13%
- $300.05+0.82%
- Market cap
- $335.2M
- $21.02B
- 1M return
- +22.48%
- +18.67%
- 1Y return
- -19.46%
- +42.62%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 5
- 7
- Recent ratings
- 4
- 15
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest CLPT
- ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
- SEC Form DEFA14A filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form DEF 14A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Fletcher R John
- SEC Form 4 filed by Girin Pascal E R
- SEC Form 4 filed by Richards Timothy T.
- Amendment: SEC Form SCHEDULE 13G/A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Burnett Joseph
Latest WST
- Sr. VP & Chief HR Officer Favorite Annette F exercised 2,817 shares at a strike of $83.47 and sold $859,753 worth of shares (2,817 units at $305.20) (SEC Form 4)
- VP, Chief Accounting Officer Winters Chad exercised 896 shares at a strike of $173.22 and sold $269,399 worth of shares (896 units at $300.67) (SEC Form 4)
- West to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.